An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Open accessThe DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index.
Abstract
Metabolic diseases, particularly diabetes mellitus (DM), are significant global public health concerns. Despite the widespread use of standard-of-care therapies, cardiovascular disease (CVD) remains the leading cause of death among diabetic patients. Early and evidence-based interventions to reduce CVD are urgently needed. Large clinical trials have recently shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) ameliorate adverse cardiorenal outcomes in patients with type 2 DM. These quite unexpected positive results represent a paradigm shift in type 2 DM management, from the sole importance of glycemic control to the simultaneous improvement of cardiovascular outcomes. Moreover, SGLT2i is also found to be cardio- and nephroprotective in non-diabetic patients. Several mechanisms, which may be potentially independent or at least separate from the reduction in blood glucose levels, have already been identified behind the beneficial effect of these drugs. However, there is still much to be understood regarding the exact pathomechanisms. This review provides an overview of the current literature and sheds light on the modes of action of novel antidiabetic drugs, focusing on inflammation, oxidative stress, and fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High-sensitivity C-reactive protein (hs-CRP), an indicator of systemic inflammation, was significantly reduced in people with T2D and cardiovascular disease treated with semaglutide.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 8×
“NF-κB and MCP-1 expression was attenuated with liraglutide treatment in hypertensive mice [70].”
BackgroundInfluentialRetractedAroor, A. R., Habibi, J., Kandikattu, H. K., Garro-Kacher, M. O., Barron, B. J., Chen, D., Hayden, M. R., Whaley‐Connell, A. T., Bender, S. B., Klein, T., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0544-4 · Cited by 76
Retracted2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Numerous CVOTs have shown the safety of GLP-1RA and the reduction in adverse cardiorenal outcomes in patients with T2DM [17,19,74].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
RYKOVA, E. Y., Klimontov, V. V., Shmakova, E. O., Korbut, A. I., Merkulova, T. I., & Kzhyshkowska, J. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041670 · Cited by 100
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
“Strong evidence has shown the anti-in fl ammatory effect of GLP-1RA (16, 17).”
BackgroundInfluentialMethylglyoxal Formation—Metabolic Routes and Consequences
Vašková, J., Sabolová, G., Pudelský, J., Palenčár, D., & Mičková, H. (2025) · Antioxidants · doi:10.3390/antiox14020212 · Cited by 71
Nuñez-Selles, A. J., Nuñez-Musa, R. A., & Guillen-Marmolejos, R. A. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1611842 · Cited by 51
Metadata
- Authors
- Balogh, D. B., Wagner, L. J., & Fekete, A.
- Affiliations
- Semmelweis University (HU)
- Corresponding author
- Fekete, Andrea
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-04-24
- Volume
- 24
- Issue
- 9
- Pages
- 7789
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10177821
- OpenAlex
- W4366989020
- Cited by
- 38
- References
- 155
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 8 · 2023: 3
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- New National Excellence Program of The Ministry for Culture and Innovation (UNKP-22-4-II-SE-2, TKP2021-EGA-24)
- Ministry of Innovation and Technology of Hungary (UNKP-22-4-II-SE-2, TKP2021-EGA-24)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- cardioprotection, type 2 diabetes, cardiovascular disease, SGLT2 inhibitors, GLP-1 receptor agonists, inflammation, oxidative stress, myocardial fibrosis, cardiorenal outcomes, drug mechanisms of action
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fibrosis, Humans, Hypoglycemic Agents, Inflammation, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. https://app.cochat.ai/papers/10.3390/ijms24097789
- The paper
- Balogh, D. B., Wagner, L. J., & Fekete, A. (2023). An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.